Dalbavancin, oritavancin and telavancin: effects and differences
Clinical review pending
These lipoglycopeptide antibiotics target Gram-positive bacteria, including MRSA. A comparison of their uses, duration of action and main risks.
What are dalbavancin, oritavancin and telavancin?
Dalbavancin (Dalvance), oritavancin (Orbactiv, also Kimyrsa) and telavancin (Vibativ) belong to the lipoglycopeptide class of antibiotics. These semisynthetic molecules are based on vancomycin’s glycopeptide structure and have an additional lipid side chain. This changes how long they remain in the body; for two of the medicines, it also enables an additional attack on bacteria. All three act against Gram-positive organisms, including MRSA. Telavancin was approved in the US in 2009; dalbavancin and oritavancin followed in 2014.
How do these antibiotics work?
Like vancomycin, these medicines inhibit bacterial cell-wall formation. They bind to the D-alanyl-D-alanine end of cell-wall building blocks, preventing the cross-linking that makes the wall stable. The lipid side chain anchors the molecules in the bacterial membrane, prolonging their activity. Oritavancin and telavancin also damage the membrane itself. All three kill Gram-positive bacteria, including MRSA.
Their duration of action is particularly important in practice. Dalbavancin has a half-life of approximately two weeks, allowing weekly doses or a single-dose treatment. Oritavancin can be given as one infusion for skin infections. In its pivotal trial program, weekly dalbavancin was noninferior to vancomycin followed by linezolid for skin infections 1. Telavancin is administered daily and is also approved for certain forms of pneumonia.
Are these medicines FDA-approved?
Yes. According to the source text, all three are approved in the US for acute bacterial skin and skin structure infections. The table lists their approval years and uses.
The US prescribing information for telavancin carries prominent warnings about kidney injury and risks to the unborn child. A pregnancy test is required before use.
What are they prescribed for?
These antibiotics treat acute bacterial skin and skin structure infections caused by susceptible Gram-positive organisms, including MRSA. Dalbavancin and oritavancin are particularly relevant when fewer infusions or a single dose would be useful—for example, to avoid keeping an intravenous line in place for a long time. Telavancin is also used for certain hospital-acquired pneumonias when other options are unsuitable.
What side effects are possible?
Citing the prescribing information, the source text lists the following common side effects:
- Nausea, headache and diarrhea
- Elevated liver enzymes with dalbavancin
- Taste disturbances and foamy urine with telavancin
More serious risks and precautions include:
- With telavancin: kidney toxicity and risks to the unborn child. Increased mortality has been observed in people with pneumonia and pre-existing moderate-to-severe kidney impairment.
- Oritavancin can interfere with certain blood-clotting tests. Intravenous unfractionated heparin must therefore not be used for a specified period after administration. Source
- Infusion-related reactions
Studies at a glance
| Medicine | FDA approval | Approved uses |
|---|---|---|
| Telavancin | 2009 | Acute bacterial skin and skin structure infections; also hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible S. aureus when alternatives are unsuitable |
| Dalbavancin | 2014; expanded in 2021 to children from birth | Acute bacterial skin and skin structure infections |
| Oritavancin | 2014 | Acute bacterial skin and skin structure infections |
References cited in the source text
Sources: FDA prescribing information for Dalvance, Orbactiv, and Vibativ; the DISCOVER dalbavancin trials (Boucher et al., The New England Journal of Medicine, 2014, DOI: 10.1056/NEJMoa1310480 1), indexed on PubMed.
Provenance and editorial review status
Adapted for Nutrient Desk from the source article. The claims and source attributions in the original text still require clinical review. This draft has not been cleared for indexing.